ALGS vs V · rev $3.6M vs P/E 33, rev $40.00B
Aligos Therapeutics Inc (ALGS) versus Visa Inc. Class A (V) — a side-by-side from cached financials, not a winner call.
Aligos Therapeutics Inc (ALGS) is a biotechnology company listed on US.
Visa Inc. Class A (V) is a credit services company listed on US. It is led by Ryan McInerney.
Latest reported ALGS revenue for 2024-12-31 was $3.6M. Net income was -$131.2M. Revenue was down 41.7% from 2023-12-31 to 2024-12-31. ALGS currently screens at market cap $44.1M.
Latest reported V revenue for 2025-09-30 was $40.00B. Net income was $20.06B. V currently screens at market cap $659.78B and trailing P/E 33.5.
ALGS currently screens at market cap $44.1M. V currently screens at market cap $659.78B and trailing P/E 33.5.
Not investment advice. Open the ALGS and V stock pages for the full models.
Not investment advice.